Treatment of primary first-episode genital herpes simplex virus infections with acyclovir: results of topical, intravenous and oral therapy.
Treatment of primary first-episode genital herpes simplex virus infections with acyclovir: results of topical, intravenous and oral therapy.
复制标题
用阿昔洛韦治疗原发性首发生殖器单纯疱疹病毒感染：局部、静脉注射和口服治疗的结果。
DOI：
10.1093/jac/12.suppl_b.79
复制
发表时间：
1983
期刊：
影响因子：
--
通讯作者：
Dragavon,J
中科院分区：
文献类型：
--
作者：
Corey,L;Benedetti,J;Critchlow,C;Mertz,G;Douglas,J;Fife,K;Fahnlander,A;Remington,ML;Winter,C;Dragavon,J
三个双盲，安慰剂对照的评价阿昔洛韦进行了首次发作生殖器疱疹感染。在一项试验中，静脉注射阿昔洛韦或生理盐水在医院超过5天。在另外两项试验中，10天的口服疗程或7天的外用阿昔洛韦疗程和各自的安慰剂在门诊部随访。定期评估包括分期检查、病变培养以及血液和血清分析。没有病人停止用药，因为不良反应，虽然四分之一的局部治疗的患者抱怨局部刺激application.The安慰剂对照的评价表明，如果在第一个7天内给予病变发生后，局部，静脉注射和口服阿昔洛韦是有用的，在缩短病程的第一次发作的原发性生殖器疱疹。静脉注射和口服阿昔洛韦的临床和病毒学效果比局部治疗更显着，在减少病毒脱落，病变完全愈合的时间，并在减少新的病变形成。全身制剂阿昔洛韦也减少了单纯疱疹病毒性尿道炎和静脉注射阿昔洛韦的单纯疱疹病毒性宫颈炎的症状。然而，无论是全身治疗，是有效的延迟或减少随后复发的频率，这可能与早期神经节感染的发展。尽管如此，阿昔洛韦治疗是原发性生殖器疱疹管理的一个重大进展。
Three double-blind, placebo-controlled evaluations of acyclovir were performed in first-episode genital herpes infections. In one trial intravenous acyclovir or saline was administered in hospital over 5 days. In the other two trials, 10-day courses of oral, or 7-day courses of topical acyclovir and respective placebos were followed up in the outpatient department. Regular assessments included staging examinations, culture of lesions and blood and serum analyses. No patient discontinued medication because of an adverse reaction, although one quarter of topically treated patients complained of local irritation on application.The placebo-controlled evaluations indicate that, if given within the first 7 days after the onset of lesions, topical, intravenous and oral acyclovir are useful in shortening the course of first-episode primary genital herpes. The clinical and virological effects of intravenous and oral acyclovir were more marked than those of topical treatment in the reduction of viral shedding; the time to complete healing of lesions; and in the reduction of new lesion formation. Systemic preparations of acyclovir also decreased the symptoms of herpes simplex virus urethritis and intravenous acyclovir those of herpex simplex virus cervicitis. Neither systemic treatment, however, was effective in delaying or reducing the frequency of subsequent recurrences, which may be related to the development of early ganglionic infection. Despite this, acyclovir treatment is a significant advance in the management of primary genital herpes.